Balyasny Asset Management L.P. Invests $3.09 Million in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Balyasny Asset Management L.P. purchased a new position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 33,536 shares of the medical instruments supplier’s stock, valued at approximately $3,090,000. Balyasny Asset Management L.P. owned approximately 0.15% of LeMaitre Vascular at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in LMAT. Raymond James Financial Inc. purchased a new stake in shares of LeMaitre Vascular during the 4th quarter worth about $14,900,000. Rockefeller Capital Management L.P. acquired a new position in shares of LeMaitre Vascular during the 4th quarter valued at about $7,787,000. Segall Bryant & Hamill LLC acquired a new position in shares of LeMaitre Vascular during the 4th quarter valued at about $5,446,000. Invesco Ltd. increased its holdings in shares of LeMaitre Vascular by 50.5% during the 4th quarter. Invesco Ltd. now owns 174,998 shares of the medical instruments supplier’s stock valued at $16,124,000 after acquiring an additional 58,720 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in shares of LeMaitre Vascular by 45.9% during the 4th quarter. JPMorgan Chase & Co. now owns 147,489 shares of the medical instruments supplier’s stock valued at $13,590,000 after acquiring an additional 46,430 shares during the last quarter. 84.64% of the stock is owned by hedge funds and other institutional investors.

LeMaitre Vascular Trading Down 1.6%

Shares of NASDAQ:LMAT opened at $80.20 on Monday. LeMaitre Vascular, Inc. has a 1-year low of $71.42 and a 1-year high of $109.58. The firm has a market capitalization of $1.81 billion, a PE ratio of 43.83, a PEG ratio of 2.22 and a beta of 0.86. The business’s 50 day moving average is $84.15 and its 200-day moving average is $93.14.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.02). LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The firm had revenue of $59.87 million for the quarter, compared to analyst estimates of $57.61 million. During the same period in the previous year, the business posted $0.44 EPS. LeMaitre Vascular’s revenue for the quarter was up 12.0% compared to the same quarter last year. On average, sell-side analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 29th. Stockholders of record on Thursday, May 15th will be issued a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a dividend yield of 1.00%. The ex-dividend date of this dividend is Thursday, May 15th. LeMaitre Vascular’s payout ratio is presently 40.40%.

Analyst Ratings Changes

LMAT has been the topic of a number of analyst reports. Wells Fargo & Company initiated coverage on LeMaitre Vascular in a report on Thursday, February 13th. They set an “equal weight” rating and a $95.00 price objective on the stock. Barrington Research lowered LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. Oppenheimer lowered LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. Finally, Lake Street Capital increased their price objective on LeMaitre Vascular from $105.00 to $110.00 and gave the company a “buy” rating in a report on Friday, February 28th. Five equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $98.14.

Insider Activity at LeMaitre Vascular

In related news, insider Trent G. Kamke sold 2,009 shares of the business’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total value of $164,979.08. Following the sale, the insider now owns 5,564 shares of the company’s stock, valued at $456,915.68. The trade was a 26.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 10.79% of the stock is owned by insiders.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.